Relative Bioavailability of Four Alternative Oral Formulations Versus the Current Tablet Formulation of Lapatinib.
Latest Information Update: 27 Aug 2023
Price :
$35 *
At a glance
- Drugs Lapatinib (Primary)
- Indications Cancer
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 15 Feb 2015 Status changed from suspended to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 12 Oct 2008 Status changed from discontinued to suspended as reported by ClinicalTrials.gov.
- 02 Sep 2008 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.